FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285275502> ?p ?o ?g. }

• W4285275502 abstract "Cognitive reserve has been hypothesized as a mechanism to explain differences in individual risk for symptomatic expression of Alzheimer's Disease (AD). Inappropriate medications may diminish cognitive reserve, precipitating the transition from preclinical AD (pAD) to a symptomatic state. To date, there is limited data on the potential impact of medication optimization as a potential tool for slowing the symptomatic expression of AD.(1) To test the efficacy of a medication therapy management intervention designed to bolster cognitive reserve in community-dwelling older adults without dementia. (2) To evaluate the efficacy of intervention by baseline pAD status.A 1-year randomized controlled trial was conducted in community-dwelling older adults without dementia. Randomization was stratified by amyloid β positron emission tomography levels.Community-based, Lexington, Kentucky.Adults 65 years or older with no evidence of dementia and reporting at least one potentially inappropriate medication as listed in the Beers 2015 criteria were recruited. The study aimed to enroll 90 participants based on the a priori sample size calculation.Medication therapy management versus standard of care.Primary outcomes were: (1) one-year changes in the Medication Appropriateness Index; (2) one-year changes in Trail Making Test B under scopolamine challenge.The medication therapy management intervention resulted in significant improvement in Medication Appropriateness Index scores. Overall, there was no beneficial effect of the medication therapy management on Trail Making Test B scores, however stratified analysis demonstrated improvement in Trail Making Test B challenged scores associated with the medication therapy management for those with elevated amyloid β positron emission tomography levels consistent with pAD.Medication therapy management can reduce inappropriate medication use in older adults at risk for AD. Our study indicated beneficial cognitive effects in those with preclinical Alzheimer's Disease. No statistically significant effects were evident in the study group as a whole, or in those without preclinical cerebral amyloidosis. Further work designed to improve the effectiveness of the medication therapy management approach and defining other preclinical pathologic states that may benefit from medication optimization are readily achievable goals for promoting improved cognitive health and potentially delaying the onset of symptomatic AD." @default.
• W4285275502 created "2022-07-14" @default.
• W4285275502 creator A5009032548 @default.
• W4285275502 creator A5025610887 @default.
• W4285275502 creator A5048341091 @default.
• W4285275502 creator A5052823984 @default.
• W4285275502 creator A5053970093 @default.
• W4285275502 creator A5067426074 @default.
• W4285275502 creator A5082973021 @default.
• W4285275502 creator A5084901723 @default.
• W4285275502 creator A5085678451 @default.
• W4285275502 creator A5087319957 @default.
• W4285275502 creator A5088960632 @default.
• W4285275502 date "2022-01-01" @default.
• W4285275502 modified "2023-09-23" @default.
• W4285275502 title "Intervention for Cognitive Reserve Enhancement in Delaying the Onset of Alzheimer’s Symptomatic Expression (INCREASE) Study: Results from a Randomized Controlled Study of Medication Therapy Management Targeting a Delay in Prodromal Dementia Symptom Progression" @default.
• W4285275502 cites W1545800183 @default.
• W4285275502 cites W1863251681 @default.
• W4285275502 cites W1931878258 @default.
• W4285275502 cites W1935403618 @default.
• W4285275502 cites W1975279736 @default.
• W4285275502 cites W1984458266 @default.
• W4285275502 cites W1984811749 @default.
• W4285275502 cites W2011195206 @default.
• W4285275502 cites W2019071176 @default.
• W4285275502 cites W2019901483 @default.
• W4285275502 cites W2039251076 @default.
• W4285275502 cites W2052300396 @default.
• W4285275502 cites W2054188228 @default.
• W4285275502 cites W2064470295 @default.
• W4285275502 cites W2072704021 @default.
• W4285275502 cites W2080265469 @default.
• W4285275502 cites W2088412175 @default.
• W4285275502 cites W2112579276 @default.
• W4285275502 cites W2127511065 @default.
• W4285275502 cites W2128339702 @default.
• W4285275502 cites W2129497119 @default.
• W4285275502 cites W2129771097 @default.
• W4285275502 cites W2137024248 @default.
• W4285275502 cites W2144907160 @default.
• W4285275502 cites W2152859618 @default.
• W4285275502 cites W2172263413 @default.
• W4285275502 cites W2559732081 @default.
• W4285275502 cites W2619945698 @default.
• W4285275502 cites W2620353619 @default.
• W4285275502 cites W2892013400 @default.
• W4285275502 cites W2900629114 @default.
• W4285275502 cites W2988223062 @default.
• W4285275502 cites W2998358053 @default.
• W4285275502 cites W3046275966 @default.
• W4285275502 cites W3091441724 @default.
• W4285275502 cites W4241984066 @default.
• W4285275502 doi "https://doi.org/10.14283/jpad.2022.55" @default.
• W4285275502 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36281668" @default.
• W4285275502 hasPublicationYear "2022" @default.
• W4285275502 type Work @default.
• W4285275502 citedByCount "1" @default.
• W4285275502 countsByYear W42852755022023 @default.
• W4285275502 crossrefType "journal-article" @default.
• W4285275502 hasAuthorship W4285275502A5009032548 @default.
• W4285275502 hasAuthorship W4285275502A5025610887 @default.
• W4285275502 hasAuthorship W4285275502A5048341091 @default.
• W4285275502 hasAuthorship W4285275502A5052823984 @default.
• W4285275502 hasAuthorship W4285275502A5053970093 @default.
• W4285275502 hasAuthorship W4285275502A5067426074 @default.
• W4285275502 hasAuthorship W4285275502A5082973021 @default.
• W4285275502 hasAuthorship W4285275502A5084901723 @default.
• W4285275502 hasAuthorship W4285275502A5085678451 @default.
• W4285275502 hasAuthorship W4285275502A5087319957 @default.
• W4285275502 hasAuthorship W4285275502A5088960632 @default.
• W4285275502 hasBestOaLocation W42852755022 @default.
• W4285275502 hasConcept C118552586 @default.
• W4285275502 hasConcept C126322002 @default.
• W4285275502 hasConcept C168563851 @default.
• W4285275502 hasConcept C169900460 @default.
• W4285275502 hasConcept C1862650 @default.
• W4285275502 hasConcept C2779134260 @default.
• W4285275502 hasConcept C2779483572 @default.
• W4285275502 hasConcept C2780665704 @default.
• W4285275502 hasConcept C2984863031 @default.
• W4285275502 hasConcept C71924100 @default.
• W4285275502 hasConceptScore W4285275502C118552586 @default.
• W4285275502 hasConceptScore W4285275502C126322002 @default.
• W4285275502 hasConceptScore W4285275502C168563851 @default.
• W4285275502 hasConceptScore W4285275502C169900460 @default.
• W4285275502 hasConceptScore W4285275502C1862650 @default.
• W4285275502 hasConceptScore W4285275502C2779134260 @default.
• W4285275502 hasConceptScore W4285275502C2779483572 @default.
• W4285275502 hasConceptScore W4285275502C2780665704 @default.
• W4285275502 hasConceptScore W4285275502C2984863031 @default.
• W4285275502 hasConceptScore W4285275502C71924100 @default.
• W4285275502 hasLocation W42852755021 @default.
• W4285275502 hasLocation W42852755022 @default.
• W4285275502 hasLocation W42852755023 @default.
• W4285275502 hasOpenAccess W4285275502 @default.
• W4285275502 hasPrimaryLocation W42852755021 @default.
• W4285275502 hasRelatedWork W1606117295 @default.
• W4285275502 hasRelatedWork W182016951 @default.
• W4285275502 hasRelatedWork W2077992747 @default.
• W4285275502 hasRelatedWork W2108804212 @default.

• next